GlaxoSmithKline (CAI:BIOC) EBITDA Margin %: 41.79% (As of Sep. 2016)


What is GlaxoSmithKline EBITDA Margin %?

GlaxoSmithKline CAI:BIOC +1.17% EBITDA Margin % is 41.79% as of Sep. 2016.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. GlaxoSmithKline's EBITDA for the three months ended in Sep. 2016 was E£112 Mil. GlaxoSmithKline's Revenue for the three months ended in Sep. 2016 was E£268 Mil. Therefore, GlaxoSmithKline's EBITDA margin for the quarter that ended in Sep. 2016 was 41.79%.

GlaxoSmithKline  (CAI:BIOC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

GlaxoSmithKline EBITDA Margin % Related Terms

GlaxoSmithKline EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline EBITDA Margin % Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
EBITDA Margin %
12.32 12.86 12.61 14.48

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.28 84.27 -0.24 -11.74 41.79

CAI:BIOC vs PRPH: EBITDA Margin % Comparison

For the Drug Manufacturers - General subindustry, GlaxoSmithKline's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline's EBITDA Margin % falls into.


GlaxoSmithKline EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

GlaxoSmithKline's EBITDA Margin % for the fiscal year that ended in Dec. 2015 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2015 )/Revenue (A: Dec. 2015 )
=147.867/1020.948
=14.48 %

GlaxoSmithKline's EBITDA Margin % for the quarter that ended in Sep. 2016 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2016 )/Revenue (Q: Sep. 2016 )
=111.866/267.715
=41.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 41.79% mean?
GlaxoSmithKline (CAI:BIOC) has a EBITDA Margin % of 41.79% as of Sep. 2016. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's EBITDA Margin % too high?
GlaxoSmithKline's current EBITDA Margin % is 41.79%. The Drug Manufacturers industry median EBITDA Margin % is 12.47. GlaxoSmithKline's value of 41.79% is 235.1% above this industry median.
How does GlaxoSmithKline's EBITDA Margin % compare to PRPH?
GlaxoSmithKline's EBITDA Margin % of 41.79% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.47. GlaxoSmithKline's value of 41.79% is 235.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline's current EBITDA Margin % of 41.79% is 235.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GlaxoSmithKline and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline's current EBITDA Margin % is 41.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current EBITDA Margin % of 41.79%. The current EBITDA Margin % is 41.79% and 235.1% above the Drug Manufacturers industry median of 12.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current EBITDA Margin % is 41.79% as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.